Voyager Therapeutics, Inc. (VYGR)
After hours:
| Previous Close | 7.55 |
| Open | 7.50 |
| Bid | 7.47 x 100 |
| Ask | 7.53 x 200 |
| Day's Range | 7.28 - 7.66 |
| 52 Week Range | 6.06 - 14.34 |
| Volume | |
| Avg. Volume | 638,787 |
| Market Cap | 407.254M |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | 2.53 |
| EPS (TTM) | 2.97 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.78 |
GlobeNewswireVoyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously a
Simply Wall St.Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Voyager Therapeutics (NASDAQ:VYGR) has had a rough week with its share price down 14%. However, a closer look at its...
Barrons.comBuy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs.
Voyager Therapeutics has surely tried investors’ patience since it came public eight years ago. The biotech firm’s stock has fallen as low as $2.50 from a peak of $30, as its early programs to treat neurological diseases didn’t pan out. Analysts at Guggenheim Securities initiated coverage of the Lexington, Mass.-based biotech with a Buy rating earlier this week.
